Description: The decrease in interest rates over the last several years has led to decreases in the maximum valuation rate and maximum nonforfeiture interest rate, and companies need to prepare for these changes.

Description: Proposes setting premiums such that inflation and age could change the premium over time, rather than prefunding. The value may be to change the approach to pricing LTC and improve the risk.

Description: This article discusses The Compact is an agreement between member states to develop and use a single set of uniform standards as the guidelines to be followed for forms to be approved, including any actuarial-type requirements.

Description: podcast update of the reinsurance section

Description: In this session, attendees will learn about the state of the developing reinsurance market for Pension Risk Transfer/Group Annuities in the United States. Discover fundamentals of the primary (group annuity) market and evaluate market forces influencing the lack of significant reinsurance volume of the same nature. This will include a compare and contrast to the PRT and PRT reinsurance markets in other regions that have seen material secondary market volume (such as the UK).

Description: Overview of the diverse Asia markets and four key themes:Rapid pace of product development, innovative underwriting solutions, Wellness, the rise of insurtech.

Description: In 2014, the SOA Product Development and Reinsurance Sections, along with the Committee for Life Insurance research engaged Reinsurance Group of America to undertake a research project on term conversion experience.

Description: The purpose of this article is to discuss some of the challenges insurance companies face when participating in the immediate annuity market for retirement income planning and to suggest ways that reinsurers could be of service to the direct writers of immediate annuities.

Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.

Description: This presentation, session number 102PD, took place at the 1999 Spring Meeting of the Society of Actuaries, held June 16-18 in Seattle. The panelists discuss the popularity of such voluntary products as critical illness, group AD&D, and group long-term disability, and their implications for reinsurers. Discussion from participants is included. From the Record of the Society of Actuaries, Vol. 25, No. 2.